[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100547846":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":23,"responsibleParty":43,"collaborators":45,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":7,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":7,"enrollmentInfo":58,"targetDuration":7,"studyType":61,"phases":7,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Ainsworth Institute of Pain Management","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","Saluda Evoke Smart SCS System","Surgical implantation of the Saluda Evoke Smart SCS System targeting the conus medullaris for stimulation",[14],{"name":15,"affiliation":5,"role":16},"Corey W Hunter, MD, FIPP","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Zoey Smith","CONTACT","(212) 203 2813","zsmith@ainpain.com",[24],{"facility":5,"status":25,"city":26,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"RECRUITING","New York","10022","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-74.00597,40.71427,{"lat":34,"lon":33},[37,39,40],{"name":19,"role":20,"phone":38,"phoneExt":7,"email":22},"212-203-2813",{"name":15,"role":16,"phone":7,"phoneExt":7,"email":7},{"name":41,"role":42,"phone":7,"phoneExt":7,"email":7},"Jeanmarie Tari, NP","SUB_INVESTIGATOR",{"type":44,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[46],{"name":47,"class":48},"Saluda Medical Pty Ltd","INDUSTRY","100547846","targeting-the-conus-medullaris-with-ecap-controlled-closed-loop-scs-for-treatment-of-chronic-pelvic-pain-hope-trial-100547846",false,"NCT06413277","Targeting the Conus Medullaris With ECAP-Controlled Closed-Loop SCS for Treatment of Chronic Pelvic Pain: HOPE Trial","Targeting the Conus Medullaris With ECAP-Controlled Closed-Loop SCS for the Treatment of Chronic Pelvic Pain: HOPE Trial","Inclusion Criteria:\n\n1. Subject is 18 years of age or older at the time of enrollment.\n2. Subject has a minimum Visual Analog Scale (VAS) score of 60 mm or higher (where 100 mm pain) at baseline.\n3. Subject has been diagnosed with chronic intractable pain of the trunk and\u002For limbs specifically related to pelvic\u002Fgenital\u002Fperineal\u002Fanorectal pain, which has been refractory to conservative therapy for a minimum of 6 months.\n4. Subject has pain resulting from a known injury (surgery or trauma).\n5. Subject has been clinically diagnosed with chronic pelvic pain (pain that occurs in the region of the pelvis), including diagnoses such as, but not limited to, complex regional pain syndrome (CRPS types 1 and 2), postsurgical pain, post-traumatic injury pain, interstitial cystitis\u002Fpainful bladder syndrome, post-hysterectomy pain, post-prostatectomy pain, vulvodynia, chronic ovarian pain, and pudendal neuralgia of a known cause.\n6. Subject is an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician.\n7. Subject is willing and capable of giving informed consent.\n8. Subject is willing and able to comply with study-related requirements, procedures, and visits.\n\nExclusion Criteria:\n\n1. Subject is pregnant or nursing.\n2. Subject is involved in a malignancy or injury claim under current litigation or has pending\u002Fapproved worker's compensation claim.\n3. Subject's mechanism of pain is unknown.\n4. Suspected cause and onset of pain are more than 30 days apart.\n5. Subject has history of small fiber neuropathy, mitochondrial disease, fibromyalgia, addiction, CRPS in secondary pain area, and\u002For atypical facial pain.\n6. Subject has been diagnosed with Crohn's Disease, Irritable Bowel Syndrome, ulcerous colitis, or any other inflammatory disease that is ongoing.\n7. Subject has a medical condition or pain in other area(s), not intended to be treated with SCS, that could interfere with study procedures, as determined by the Investigator.\n8. Subject has a history of sexual abuse and\u002For sexual trauma.\n9. Subject has a history of unmanaged depression or anxiety that pre-dates the onset of symptoms.\n10. Subject is using greater than 100 MME (morphine milligram equivalents) of opioids at baseline.\n11. Subject shows evidence of an active, disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention, and\u002For ability to evaluate treatment outcomes.\n12. Subject has previous neuromodulation experience including SCS (Spinal Cord Stimulator) and\u002For DRG (Dorsal Root Ganglion).\n13. Subject has an existing drug pump and\u002For SCS system, or another active implantable device such as a pacemaker, deep brain stimulator, or sacral nerve stimulator.\n14. Subject is concomitantly participating in another clinical study.","ALL","18 Years",{"count":59,"type":60},20,"ESTIMATED","OBSERVATIONAL","The aim of the study is to evaluate the effectiveness of using ECAP (electrically evoked compound action potential)-controlled CL (closed-loop) SCS (spinal cord stimulation) to treat chronic pelvic pain by stimulating an area in the spine called the conus medullaris (the lowermost tapering extremity of the spinal cord).",[64,65],"Chronic Pelvic Pain","Pudendal Neuralgia",[64,65,67],"Levator Ani Syndrome","2024-05-10",{"date":70,"type":71},"2024-05-14","ACTUAL",{"date":73,"type":71},"2024-02-05",{"date":75,"type":60},"2027-01-01",{"name":5,"class":6},1]